Elicio Therapeutics, Inc.
No enriched coverage for $ELTX in the last 7 days.
No SEC Form 4 filings for $ELTX in the last 30 days.
See all $ELTX insider activity →Elicio Therapeutics (ELTX) announced that new analyses from its Phase 2 AMPLIFY-7P study of ELI-002 7P in pancreatic cancer will be presented at ESMO Congress 2026. The findings aim to refine the Phase 3 development strategy, though the study did not meet its primary endpoint.
Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an a
Elicio Therapeutics (Nasdaq: ELTX) said it closed a $15 million registered direct offering, selling 4,380,313 shares of common stock at gross proceeds of about $15 million. The company will use net proceeds to fund Phase 1 development of ELI-002 7P in metastatic PDAC, pipeline work, and general corporate purposes.
Recent ELTX coverage spans financial news, corporate actions and market movers.
The announcement may generate short‑term interest but no immediate catalyst for price movement.
This is a fresh SEC filing tied to quarterly results, but the scraped text does not include the actual financial numbers or guidance details.
The financing reduces near-term cash risk and funds the next clinical step, but the share issuance can pressure the stock via dilution.
Dilutive equity financing to fund Phase 1 development of ELI-002 7P; near-term pressure likely from dilution/overhang into the July 6 close.
The 8-K discloses a new equity financing structure (common stock + pre-funded warrants) that can dilute holders and affect near-term liquidity/financing expectations.
AlphAI scores every news story that mentions ELTX with an AI model for sentiment and relevance, and aggregates insider trades from Elicio Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Elicio Therapeutics (ELTX) announced that new analyses from its Phase 2 AMPLIFY-7P study of ELI-002 7P in pancreatic cancer will be presented at ESMO Congress 2026. The findings aim to refine the Phase 3 development strategy, though the study did not meet its primary endpoint.
1 min readElicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an a
3 min readElicio Therapeutics (Nasdaq: ELTX) said it closed a $15 million registered direct offering, selling 4,380,313 shares of common stock at gross proceeds of about $15 million. The company will use net proceeds to fund Phase 1 development of ELI-002 7P in metastatic PDAC, pipeline work, and general corporate purposes.
4 min readElicio Therapeutics (NASDAQ:ELTX) shares fell 32.5% after it announced a $15M registered direct offering of 4,380,313 shares. The company plans to use net proceeds, plus existing cash, for Phase 1 development of ELI-002 7P in metastatic pancreatic cancer, pipeline, and working capital. Closure expected around July 6, 2026.
4 min readElicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 tm2619637d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 1, 2026, between Elicio Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified
2 min readElicio Therapeutics (Nasdaq: ELTX) priced a $15 million registered direct offering to sell 4,380,313 shares of common stock, expected to close around July 6, 2026. Gross proceeds are about $15M before fees. Net proceeds will fund Phase 1 development of ELI-002 7P in metastatic PDAC and other pipeline/work capital.
3 min readuniQure (QURE) surged 78% after the FDA said the 3-year Phase I/II analysis for AMT-130 in Huntington’s could serve as primary evidence for an accelerated BLA; QURE plans to file in Q3 2026. Elicio (ELTX) rose 71% on Phase 2 AMPLIFY-7P responses. Lunai (LNAI) gained 40% on CEO updates; other biotech movers included CLPT, PLRZ and FTH.
5 min readElicio Therapeutics (ELTX) reported post-hoc results from its Phase 2 AMPLIFY-7P trial of ELI-002 7P in resected mKRAS-driven pancreatic cancer. The study did not meet its primary DFS endpoint in the overall intent-to-treat population, which the company attributed partly to more R1 resections in the ELI-002 arm. In R0 patients (n=121), DFS improved (HR 0.65, p=0.048; median 23.8 vs 12.8 months). Elicio plans a refined Phase 3 focused on R0 patients and additional dosing, and said current cash su
6 min readElicio Therapeutics reported a net loss of $39.6 million and an EPS of $(2.58) for the year ended December 31, 2025, an improvement from 2024. The company's operating loss was $37.7 million, and its cash reserves are projected to fund operations into Q3 2026. Key business highlights include clinical progress for ELI-002 7P in Phase 2, expansion of preclinical programs, and a strategic shift towards off-the-shelf immunotherapies.
3 min readBOSTON, Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Elicio Therapeutics, Inc. ( Nasdaq: ELTX, "Elicio" or the "Company" ) , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on September 15, 2025, Elicio granted an ...
2 min read
